Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References EntrestoⓇ peak sales expectations of at least USD 5bn driven by remaining patient potential, guidelines, geographic expansion In-market indications ~70% of eligible HFrEF patients not currently treated in G71 US expanded label increased addressable population to 5m Guideline implementation ACC ECDP, ESC and national HF guidelines² recommend ARNI 1L Entresto to replace ACE/ARB in all appropriate HFrEF patients Partnerships to implement quality metrics for HF care Geographic expansion Strong momentum in HFrEF in China Long-term growth in Japan across CHF and HTN Additional growth outside of G7 based on expanded HF label and HTN People + excellence in operations See appendix for references HFrEF - Heart Failure with reduced Ejection Fraction ACC American College of Cardiology ECDP - Expert Consensus Decision Pathway ESC - European Society of Cardiology HF Heart Failure ARNI - Angiotensin Receptor Neprylisin Inhibitor ACE-Angiotensin Converting Enzyme ARB - Angiotensin II Receptor Blocker 28 Investor Relations | Q3 2021 Results ✓ NOVARTIS | Reimagining Medicine

View entire presentation